Workflow
REPUBLIC HC(08357)
icon
Search documents
REPUBLIC HC发布中期业绩,亏损净额121.67万新加坡元 同比扩大715.78%
Zhi Tong Cai Jing· 2025-08-04 10:49
REPUBLIC HC(08357)发布截至2025年6月30日止6个月的中期业绩,该集团取得收益373.45万新加坡 元,同比减少16.67%;来自持续经营业务的期间亏损净额121.67万新加坡元,同比增加715.78%;每股亏损 0.2新加坡分。 ...
REPUBLIC HC(08357)发布中期业绩,亏损净额121.67万新加坡元 同比扩大715.78%
智通财经网· 2025-08-04 10:48
智通财经APP讯,REPUBLIC HC(08357)发布截至2025年6月30日止6个月的中期业绩,该集团取得收益 373.45万新加坡元,同比减少16.67%;来自持续经营业务的期间亏损净额121.67万新加坡元,同比增加 715.78%;每股亏损0.2新加坡分。 ...
REPUBLIC HC(08357) - 2025 - 中期业绩
2025-08-04 10:36
香港交易及結算所有限公司及香港聯合交易所有限公司(「聯交所」)對本公告的內容概不負責, 對其準確性或完整性亦不發表任何聲明,並明確表示概不就因本公告全部或任何部分內容而產 生或因倚賴該等內容而引致的任何損失承擔任何責任。 Republic Healthcare Limited (於開曼群島註冊成立之有限公司) (股份代號:8357) 截至2025年6月30日止六個月之中期業績公告 Republic Healthcare Limited(「本公司」,連同其附屬公司統稱「本集團」)董事(「董 事」)會茲公佈本集團截至2025年6月30日止六個月之未經審核簡明綜合財務業 績。本公告遵照聯交所GEM證券上市規則(分別為「GEM」及「GEM上市規則」) 有關中期業績初步公告隨附資料的相關規定,載列本公司2025年中期報告(「2025 年中期報告」)的全文。2025年中期報告之印刷本,將於適當時候按照GEM上市規 則規定的方式寄發予本公司股東,並將於聯交所網站 www.hkexnews.hk 及本公司 網站 republichealthcare.asia 可供查閱。 代表 Republic Healthcare Limi ...
REPUBLIC HC(08357) - 2024 - 年度财报
2025-03-27 10:01
Financial Performance - The company recorded revenue of approximately SGD 8.7 million for the fiscal year 2024, a decrease of about 13% from SGD 10.0 million in fiscal year 2023[9] - The company reported a loss of approximately SGD 0.20 million in fiscal year 2024, significantly improved from a loss of SGD 0.86 million in fiscal year 2023[9] - Revenue from consultation services, medical examination services, and treatment services were approximately SGD 1.24 million, SGD 2.10 million, and SGD 5.32 million, accounting for about 14.3%, 24.2%, and 61.5% of total revenue respectively[15] - The company recorded total revenue of approximately SGD 8.7 million for the fiscal year 2024, a decrease of about SGD 1.3 million or 13% compared to SGD 10.0 million in fiscal year 2023[18] - Revenue breakdown for fiscal year 2024 includes: SGD 1,235,000 (14.2%) from consultations, SGD 2,097,000 (24.2%) from medical examinations, and SGD 5,324,000 (61.5%) from treatment services[19] - Total comprehensive loss for the year was approximately SGD 201,000, a reduction from SGD 862,000 in fiscal year 2023[31] Operational Developments - The company established a presence in the Philippines in 2024, marking a significant step in its regional expansion efforts, with educational services set to launch in Q3 2025[9] - The company is facing challenges in its online healthcare business due to intense competition, leading to a temporary suspension of online business expansion to enhance long-term viability[9] - The company anticipates ongoing pressure from global economic uncertainty and rising operational costs, alongside increased competition from online healthcare service providers[15] - The company operates five DTAP clinics located in Robertson, Novena, Holland Village, Kovan, and Paragon[12] Cost Management - Cost-saving measures have helped mitigate the overall loss despite the decrease in revenue[9] - Employee benefits expenses slightly decreased to approximately SGD 4.2 million in the current year, reflecting cost efficiency measures[23] - Other operating expenses decreased by approximately 24.6% to about SGD 1.94 million, primarily due to lower-than-expected marketing expenses[27] Cash Flow and Equity - The company's total equity as of December 31, 2024, was approximately SGD 12.6 million, compared to SGD 12.8 million in fiscal year 2023[37] - The company had cash and bank balances of approximately SGD 11.4 million as of December 31, 2024, down from SGD 11.9 million in fiscal year 2023[37] - Operating cash flow net amount was approximately SGD 0.1 million, a significant improvement from a net cash outflow of SGD 0.9 million in fiscal year 2023[37] - The capital debt ratio as of December 31, 2024, was approximately 6%, compared to 7.6% in fiscal year 2023[37] Strategic Plans - The group plans to establish a new online business branch for Dtap, with an estimated launch around May 2025[56] - The primary use of funds will be for future expansion of the group's existing business and potential acquisitions or investments when suitable opportunities arise[57] - The board has decided to reallocate the net proceeds for operational funding instead of expanding the treatment center business, as it is not deemed the best time for such expansion[57] Governance and Compliance - The company has confirmed compliance with the GEM Listing Rules regarding related party transactions, with no significant related party transactions outside of disclosed employment contracts[108] - The company has a non-competition agreement in place with its controlling shareholders, effective since May 18, 2018, to prevent competition in its business areas[110] - The company is committed to maintaining high standards of corporate governance and regularly reviews its governance practices[137][139] - The company has complied with all relevant laws and regulations without any significant violations during the year[128] Board and Management - The board consists of over 50% independent non-executive directors, ensuring a balanced composition for independent judgment[147] - The company has appointed independent non-executive director Ms. Jiang Li'e effective from September 30, 2024, to replace Mr. Kevin John Chia, who will resign on the same date[95] - The company is committed to ensuring that all directors are subject to rotation and re-election at least once every three years during the annual general meeting[178] - The Compensation Committee held two meetings during the year ending December 31, 2024, to review and provide recommendations on the remuneration of directors and senior management[175] Risk Management - The group has identified key risks including the ability to attract and retain skilled professionals, which is critical for maintaining service quality and operational performance[47] - The internal control system is designed to minimize risks associated with daily operations, with the board overseeing its effectiveness[185] - The audit committee has reviewed the effectiveness of the risk management and internal control systems, finding them adequate and effective for the review year[186]
REPUBLIC HC(08357)附属拟2141.8万披索购买菲律宾物业
智通财经网· 2025-03-26 15:03
Core Viewpoint - Republic HC's subsidiary, Republic Resources Corporation, has entered into an agreement to purchase a property in the Philippines for 21.418 million pesos, indicating a strategic move to enhance its office space and long-term investment potential [1][2]. Group 1: Property Acquisition Details - The property is located at Unit 1605, The Gentry Corporate Plaza, Makati City, with a saleable area of approximately 80 square meters [1]. - The property is currently under construction and will be developed into a mixed-use project, including office space and multi-level parking [1]. - The seller is required to complete the property according to the architectural plans by April 2025, with the possibility of extensions as per the agreement [1]. Group 2: Investment Rationale - The property is situated in Manila's prime business district, offering excellent long-term investment potential [2]. - It is a freehold property, providing additional security and ownership benefits [2]. - The acquisition price is significantly discounted compared to the current market price, making it an attractive investment [2]. - Given the rising rental costs in the area, purchasing the property is more economical than leasing, providing financial stability and capital appreciation potential [2].
REPUBLIC HC(08357) - 2024 - 年度业绩
2025-03-21 14:22
Financial Performance - For the fiscal year 2024, Republic Healthcare Limited reported revenue of approximately SGD 8.7 million, a decrease of about 13% from SGD 10.0 million in fiscal year 2023[12]. - The company recorded a loss of approximately SGD 0.20 million for the fiscal year 2024, compared to a loss of SGD 0.86 million in fiscal year 2023[12]. - The group's total revenue for the fiscal year 2024 was approximately SGD 8.7 million, a decrease of about SGD 1.3 million or 13% compared to SGD 10.0 million in fiscal year 2023[22]. - The total comprehensive loss for the year was approximately SGD 201,000, a decrease from SGD 862,000 in the fiscal year 2023[38]. - The net cash from operating activities was approximately SGD 0.1 million, compared to a net cash outflow of SGD 0.9 million in the fiscal year 2023[45]. - The group had cash and bank balances of approximately SGD 11.4 million as of December 31, 2024, down from SGD 11.9 million in the fiscal year 2023[45]. - The capital debt ratio at year-end was approximately 6%, a decrease from 7.6% in the fiscal year 2023[45]. - The employee costs for the year were approximately SGD 4.2 million, down from SGD 4.4 million in the fiscal year 2023[53]. - The group recorded a tax credit of approximately SGD 5,391 for the current year, compared to a tax expense of SGD 26,888 in fiscal year 2023[36]. - The company reported no dividend payment for the current fiscal year, consistent with the previous year[96]. Revenue Sources - Revenue from consultation services, medical examination services, and treatment services were approximately SGD 1,235,226 (14.2%), SGD 2,096,982 (24.2%), and SGD 5,324,389 (61.5%) respectively, contributing to the total revenue[24]. - The decrease in revenue was primarily due to increased competition in the primary healthcare sector and rising costs in core areas such as sexual health, men's health, and women's health[12]. Operational Challenges - Due to intense competition in the e-commerce market, the online healthcare business faced challenges, leading the company to pause its online expansion to refine strategies and improve backend systems[12]. - The group anticipates ongoing pressure from global economic uncertainty leading to increased operating costs and intensified competition from online healthcare service providers[19]. - Geopolitical tensions and ongoing inflation pressures are expected to increase operational costs for the company[14]. - The group expects to face challenges from both intensified competition in primary healthcare and overall economic pressures affecting profitability and inflation-related cost increases[23]. Strategic Initiatives - The company aims to enhance efficiency, optimize costs, and solidify its market position to drive sustainable growth despite industry challenges[13]. - The company made progress in expanding its education business, successfully establishing a presence in the Philippines, with plans to launch operations in the third quarter of 2025[12]. - The group aims to focus on cost optimization, operational efficiency, and strategic growth measures to navigate challenges and promote long-term sustainable development[21]. Employee and Staffing - The number of employees (including part-time staff) decreased from 37 in fiscal year 2023 to 34 in fiscal year 2024[30]. - Employee benefit expenses slightly decreased to approximately SGD 4.2 million in the current year[29]. - The company is actively monitoring labor market changes to adjust compensation plans for retaining talented employees[66]. Corporate Governance - The company is committed to maintaining high standards of corporate governance and regularly reviews its practices[152]. - The board consists of more than 50% independent non-executive directors, ensuring a balanced composition for effective independent judgment[179]. - The company has established three board committees: the audit committee, nomination committee, and remuneration committee, to oversee specific aspects of the company's affairs[192]. - The audit committee includes three independent non-executive directors, with Mr. Yang serving as the chairman, ensuring independence and objectivity in financial reporting[194]. - The board of directors confirmed compliance with the GEM listing rules regarding securities trading standards[107]. Shareholder Information - As of December 31, 2024, Dr. Chen holds 350,000,000 shares, representing 56.09% of the company's issued shares of 624,000,000[140]. - Cher Sen Holdings Limited, wholly owned by Dr. Chen, holds the same number of shares, indicating a significant ownership concentration[141]. - The company confirms compliance with GEM listing rules, maintaining a public float of at least 25% of its issued shares[154]. Future Outlook - The company remains optimistic about the continued growth and reputation of the healthcare industry in Singapore despite increasing competition[14]. - The company has allocated SGD 222,000 for the establishment of a new healthcare-related education business, with ongoing efforts in this area[72]. - The remaining unutilized proceeds are expected to be used for operational funding, with a focus on adapting to changing market conditions[67][69].
REPUBLIC HC(08357) - 2024 - 中期业绩
2024-09-20 08:31
香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責,對其準確性或完整性亦不 發表任何聲明,並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失 承擔任何責任。 Republic Healthcare Limited ( 於開曼群島註冊成立之有限公司) (股份代號:8357) 有關截至2024年6月30日止六個月之 中期業績公告之 澄清公告 茲提述Republic Healthcare Limited(「本公司」,連同其附屬公司統稱「本集團」)截至2024年6 月30日止六個月之中期業績公告(「中期業績公告」)。除非文義另有所指,本公告所使用詞 彙與中期業績公告所界定者具有相同涵義。 本 公 司 謹 此 澄 清 , 本 集 團 截 至 2024 年 6 月 30 日 止 六 個 月 之 未 經 審 核 簡 明 綜 合 財 務 狀 況 表 (「 2024 年 中 期 資 產 負 債 表 」)中 出 現 疏 忽 分 類 錯 誤 , 即 根 據 財 務 報 告 準 則 第 7 號 , 其 中 1,994,217新加坡元之「按攤銷成本列賬之其他金融資產」應分類為「現金及現 ...
REPUBLIC HC(08357) - 2024 - 中期业绩
2024-08-02 08:58
Financial Performance - Republic Healthcare Limited reported revenue of approximately SGD 4.5 million for the six months ended June 30, 2024, a decrease of about 16.7% compared to SGD 5.4 million in the same period last year[5]. - The gross profit for the period was approximately SGD 3.1 million, down about 11.4% from SGD 3.5 million in the previous year[5]. - Revenue for the six months ended June 30, 2024, decreased to SGD 4.48 million from SGD 5.40 million in the same period last year, representing a decline of approximately 17%[7]. - Total revenue for the six months ended June 30, 2024, was SGD 4,481,738, a decrease of 17% from SGD 5,403,458 for the same period in 2023[30]. - Treatment services revenue decreased to SGD 2,763,858, down 11.7% from SGD 3,128,131 in the previous year[30]. - Medical examination services revenue fell to SGD 1,074,389, a decline of 19.3% from SGD 1,331,375 in the prior year[30]. - The company reported a loss attributable to owners of SGD (156,057) for the six months ended June 30, 2024, compared to a loss of SGD (260,321) in the same period of 2023[34]. - The company recorded a net loss of SGD 0.15 million for the current period, an improvement from a net loss of SGD 0.28 million in the previous year, attributed to enhanced cost control measures[6]. - Basic loss per share for the six months ended June 30, 2024, was SGD (0.03), an improvement from SGD (0.04) in the previous year[34]. Operational Challenges - The decline in medical business sales was approximately 12%, significantly impacted by the closure of a treatment center, which affected overall revenue and patient volume[5]. - Increased competition from both new entrants and established companies has intensified, with competitors ramping up marketing efforts and launching new services[5]. - Economic factors have influenced patient spending patterns, with rising living costs leading patients to seek more affordable healthcare options[5]. - Recent revisions to healthcare regulations have resulted in increased operational costs and tighter compliance requirements, impacting revenue[5]. - A shift towards telemedicine and online consultation services has occurred, which typically have lower profit margins compared to in-person consultations[5]. Financial Position - Non-current assets as of June 30, 2024, totaled SGD 1.35 million, down from SGD 2.08 million as of December 31, 2023[8]. - Current assets increased slightly to SGD 13.59 million from SGD 13.56 million as of December 31, 2023[8]. - Total liabilities decreased to SGD 2.34 million from SGD 2.89 million as of December 31, 2023[9]. - The total cash and cash equivalents decreased by SGD 1,788,214 for the six months ended June 30, 2024, compared to an increase of SGD 700,821 in the same period of 2023[11]. - The cash and cash equivalents at the beginning of the period were SGD 11,934,070, while at the end of the period, they were SGD 10,145,856[11]. - Trade receivables as of June 30, 2024, amount to SGD 140,360, an increase from SGD 65,251 as of December 31, 2023[43]. - Trade payables as of June 30, 2024, total SGD 247,420, a decrease from SGD 334,759 as of December 31, 2023[50]. - The total carrying amount of property, plant, and equipment as of June 30, 2024, was SGD 1,904,887[36]. Strategic Initiatives - The company aims to expand its network of treatment centers and diversify its service offerings in high-potential areas to meet increasing comprehensive care demands[62]. - Investment in telemedicine platforms, electronic health records, and advanced diagnostic tools is crucial for improving patient care and operational efficiency[62]. - The strategy to expand healthcare education services is seen as a key growth area, with tailored training programs aimed at addressing industry skill gaps[63]. - The company anticipates that its healthcare education initiatives will contribute revenue in the third quarter of 2024, aligning with optimistic expectations for the sector[64]. - The online healthcare business platform "Quinn" has been launched, with ongoing improvements to user interface and experience[83]. Governance and Compliance - The financial statements have been prepared in accordance with International Financial Reporting Standards and applicable GEM listing rules, ensuring consistency with the previous audited financial statements[13]. - The company adopted all applicable new or revised International Financial Reporting Standards effective from January 1, 2023, with no significant impact on accounting policies or reported amounts[13]. - The Audit Committee, consisting of three independent non-executive directors, reviewed the unaudited consolidated financial statements and found them compliant with applicable accounting standards[100]. - The company has adopted a code of conduct for securities trading that complies with GEM Listing Rules, confirming full compliance by all directors during the reporting period[90]. Shareholder Information - As of June 30, 2024, Dr. Chen holds 350,000,000 shares, representing 56.09% of the company's issued share capital of 624,000,000 shares[93]. - Cher Sen Holdings Limited, wholly owned by Dr. Chen, holds 100% of its shares, indicating Dr. Chen's beneficial ownership[95]. - The total number of issued shares as of June 30, 2024, is 624,000,000[96]. - The company has not granted or agreed to grant any options under the share option scheme since its adoption, and there are no unexercised options as of June 30, 2024[93].
REPUBLIC HC(08357) - 2023 - 年度财报
2024-04-08 08:33
Financial Performance - The company recorded total revenue of approximately SGD 10 million for the fiscal year ending December 31, 2023, representing an increase of about 11.11% compared to SGD 9 million in the previous fiscal year[12]. - The company incurred a loss of approximately SGD 0.86 million in 2023, an improvement from a loss of SGD 1.5 million in 2022[12]. - Total revenue for the fiscal year 2023 was approximately SGD 10,002,000, an increase from SGD 9,040,000 in 2022, representing a growth of 10.7%[22]. - The overall comprehensive loss for the fiscal year 2023 was approximately SGD 862,000, a reduction from a loss of SGD 1,492,000 in 2022, indicating an improvement of 42.1%[35]. Revenue Breakdown - Revenue from consultation services, medical examination services, and treatment services amounted to approximately SGD 1.38 million, SGD 2.61 million, and SGD 6.02 million, respectively, accounting for about 13.8%, 26.0%, and 60.2% of total revenue[18]. - Revenue from medical examinations significantly increased by approximately SGD 639,000, contributing to a total of SGD 2,606,000, which is 26.0% of total revenue in 2023 compared to 21.7% in 2022[22]. Operational Challenges - The company faced challenges in its new business areas, particularly in telemedicine and education, with delays in launching an online portal due to necessary backend software improvements[12]. - Increased operational costs due to inflation, including labor and rental expenses, are anticipated to pressure the company's profitability[19]. - Global inflation and geopolitical tensions are expected to create uncertainty in the economic outlook, impacting operational costs for the company[13]. Future Plans - The company plans to restart the online portal in late 2024 after completing the acquisition of a newly established education company in February 2024[12]. - The company plans to establish a new online business branch for Dtap, with an estimated launch around May 2024[64]. - The company plans to utilize the remaining net proceeds for future expansion of existing businesses and potential acquisitions when suitable opportunities arise[65]. Financial Position - Cash and cash equivalents amounted to approximately SGD 11.9 million as of December 31, 2023, compared to SGD 10.8 million in 2022, indicating a strong liquidity position[40]. - The total equity as of December 31, 2023, was approximately SGD 12.8 million, down from SGD 13.6 million in 2022[40]. - The capital debt ratio as of December 31, 2023, was approximately 7.6%, an increase from 5.7% in 2022, reflecting a slight increase in leverage[40]. Employee and Operational Costs - Employee benefits expenses slightly decreased to approximately SGD 4.4 million in 2023 from the previous year, attributed to the closure of treatment centers and sale of two entities[27]. - Other operating expenses increased by 24.8% to approximately SGD 2.57 million in 2023, primarily due to higher-than-expected marketing expenses[31]. - The total employee count as of December 31, 2023, was 37, down from 39 in the fiscal year 2022, with employee costs remaining stable at approximately SGD 4.4 million[49]. Investments and Acquisitions - The company has allocated SGD 2,031,000 for the renovation and acquisition of fixed assets for a new DTAP treatment center in Jurong[67]. - The company has spent SGD 1,220,000 for the renovation and acquisition of fixed assets for a new SA treatment center in Jurong as of December 31, 2023[67]. - The company has invested approximately SGD 222,000 to establish a new healthcare-related education business as of December 31, 2023[69]. Governance and Compliance - The company has adopted corporate governance practices in accordance with the GEM Listing Rules, ensuring accountability and transparency[151]. - The board of directors consists of four members, with independent non-executive directors accounting for over 50%[156]. - The company has confirmed compliance with the non-competition agreement by all controlled persons for the current year[123]. Risk Management - The group has identified key risks including reliance on skilled professionals and potential impacts from regulatory changes[53][56]. - The company has implemented policies and procedures for risk management and internal controls, with the board responsible for monitoring their effectiveness[193]. - The Audit Committee is responsible for reviewing the effectiveness of the Group's risk management and internal control systems[170]. Shareholder Information - The company reported no dividends for the fiscal year 2023, consistent with the previous year[90]. - As of December 31, 2023, Dr. Chen held 350 million shares, representing 56.09% of the company's issued shares[130]. - The company confirms it maintains sufficient public float, with at least 25% of issued shares held by the public as of the report date[138].
REPUBLIC HC(08357) - 2023 - 年度业绩
2024-03-28 14:25
Financial Performance - The group recorded revenue of approximately SGD 10 million for the fiscal year ending December 31, 2023, an increase of about 11.11% compared to SGD 9 million for the fiscal year 2022[14]. - The group incurred a loss of approximately SGD 0.86 million in 2023, an improvement from a loss of SGD 1.5 million in 2022[14]. - The group's total revenue for the year ended December 31, 2023, was approximately SGD 10.0 million, an increase of about SGD 1.0 million or 11.11% compared to SGD 9.0 million in the fiscal year 2022[22]. - Revenue from medical examination services increased significantly by approximately SGD 639,000, while treatment and consultation services saw slight increases[24]. - The revenue breakdown for 2023 included consultation services at SGD 1,379,000 (13.8%), medical examination services at SGD 2,606,000 (26.0%), and treatment services at SGD 6,017,000 (60.2%) of total revenue[24]. - The total comprehensive loss for the year was approximately SGD 862,000, a decrease from a total comprehensive loss of approximately SGD 1,492,000 in the fiscal year 2022[37]. - Employee benefits expenses slightly decreased to approximately SGD 4.4 million due to the closure of consultation centers and the sale of two physical locations[29]. - The group recorded an income tax expense of approximately SGD 26,888 in the current year, compared to an income tax credit of SGD 28,471 in the fiscal year 2022[36]. - The group has decided not to declare a final dividend for the year, consistent with the previous fiscal year[39]. - The group had cash and bank balances of approximately SGD 11.9 million as of December 31, 2023, compared to SGD 10.8 million in the fiscal year 2022[42]. - The net current assets of the group were approximately SGD 11.2 million as of December 31, 2023, down from SGD 12 million in the fiscal year 2022[42]. - The capital debt ratio as of December 31, 2023, was approximately 7.6%, an increase from 5.7% in the fiscal year 2022[42]. - The net cash generated from operating activities was approximately SGD 0.9 million for the fiscal year 2023, compared to a net cash used of SGD 0.7 million in the fiscal year 2022[42]. - The group recorded a foreign exchange gain of approximately SGD 117,000 due to the depreciation of the Hong Kong dollar against the Singapore dollar, compared to a loss of SGD 23,000 in the fiscal year 2022[45]. Operational Changes - The closure of the Duo Galleria treatment center in 2023 was due to lease expiration and a shortage of doctors within the group[14]. - The online portal for telemedicine and education services has been trialed but is currently paused for backend software improvements, with plans to relaunch in late 2024[14]. - The group operates five DTAP treatment centers located in Robertson, Novena, Holland Village, Kovan, and Paragon[16]. - The group anticipates facing pressures from global inflation leading to increased operating costs and heightened competition from online healthcare service providers[21]. - Other operating expenses rose by 24.8% to approximately SGD 2.57 million in the current year, primarily due to higher-than-expected marketing expenses[33]. - The group’s total employee count, including part-time staff, was 37 in 2023, down from 39 in 2022[30]. - The company has spent approximately SGD 299,000 to establish a new online business branch for DTAP, with the platform expected to launch around May 2024[66][71]. - SGD 424,000 was utilized to explore new opportunities for vertical expansion, including the establishment of a dedicated medical treatment center[71]. - The company plans to acquire equity in a potential enterprise, with SGD 500,000 allocated for this purpose, expected to be utilized in the second half of FY2025[67]. Corporate Governance - The company is committed to maintaining high standards of corporate governance and regularly reviews its governance practices[138]. - The company has complied with all relevant laws and regulations affecting its business operations during the year[143]. - The company has adopted and complied with all applicable corporate governance codes as per the GEM Listing Rules for the year ending December 31, 2023[153]. - The board consists of four directors, with independent non-executive directors making up over 50% of the board members as of December 31, 2023[158]. - All directors confirmed full compliance with the trading standards set forth in the GEM Listing Rules for the year ending December 31, 2023[154]. - The board held a total of four meetings during the year, with all directors actively participating in committee meetings and shareholder meetings[164]. - The company has ensured that all directors received formal training upon their initial appointment to understand their responsibilities and the company's operations[162]. - Independent non-executive directors contributed significantly to the board by providing rich operational and financial expertise[159]. - The company has established a mechanism for continuous professional development for all directors, encouraging participation in relevant training courses[162]. - The board is responsible for overseeing the business management and overall performance of the group, ensuring necessary financial and human resources support[155]. - The company has maintained a balanced composition of executive and non-executive directors to ensure independent judgment[158]. - The company has taken out appropriate insurance for directors to cover any liabilities arising from their duties[160]. - The board has adopted a diversity policy and aims to appoint at least one female director by December 31, 2024, in compliance with GEM Listing Rule 17.104[166]. - The audit committee is responsible for reviewing the financial statements and ensuring the independence of external auditors[171]. - The nomination committee is tasked with evaluating candidates for board positions and ensuring compliance with governance policies[174]. - The company has a policy for the rotation and re-election of directors, requiring one-third of the board to retire at the annual general meeting[187]. Risk Management - The company has implemented policies and procedures for risk management and internal controls, with the board responsible for monitoring their effectiveness[195]. - The board confirmed that the risk management and internal control systems are designed to manage risks rather than eliminate them, providing reasonable assurance against material misstatements or losses[195]. - The company has appointed a compliance officer since September 30, 2020, to oversee compliance matters[200]. - The board is aware of its responsibility to prepare the annual report and audited consolidated financial statements to reflect the group's condition fairly[193]. - There are no significant uncertainties that may cast doubt on the company's ability to continue as a going concern[194]. Shareholder Information - The company confirms it maintains a sufficient public float, with at least 25% of its issued shares held by the public as of the report date[140]. - The total remuneration for external auditors for the year ending December 31, 2023, amounted to SGD 158,600, with SGD 148,000 for audit services and SGD 10,600 for non-audit services[191]. - The company has not entered into any stock-linked agreements during the fiscal year ending December 31, 2023[142]. - The company has not disclosed any tax reliefs related to shareholder equity holdings[146]. - The company will ensure that no director participates in determining their own remuneration, maintaining independence in the process[185].